PUBLISHER: TechNavio | PRODUCT CODE: 1581187
PUBLISHER: TechNavio | PRODUCT CODE: 1581187
Hypoparathyroidism Market 2024-2028
The hypoparathyroidism market is forecasted to grow by USD 474.9 million during 2023-2028, accelerating at a CAGR of 7.6% during the forecast period. The report on the hypoparathyroidism market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increased awareness programs for thyroid treatment, approval of new medications for hypoparathyroidism, and expansion in drug discovery efforts.
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 7.3% |
CAGR | 7.6% |
Incremental Value | $474.9 mn |
Technavio's hypoparathyroidism market is segmented as below:
By Product
By Distribution Channel
By Geographical Landscape
This study identifies the growing use of inorganic growth strategies by vendors as one of the prime reasons driving the hypoparathyroidism market growth during the next few years. Also, emergence of new therapies for hypoparathyroidism and rising number of clinical trials for hypoparathyroidism treatment will lead to sizable demand in the market.
The report on the hypoparathyroidism market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hypoparathyroidism market vendors that include AdvaCare Pharma, Alkem Laboratories Ltd., Ascendis Pharma AS, AstraZeneca Plc, Cipla Inc., COSCIENS BIOPHARMA, Extend Biosciences Inc, F. Hoffmann La Roche Ltd., La Renon Healthcare Pvt. Ltd., LLOYD Inc., Lupin Ltd., Merck and Co. Inc., Pfizer Inc., Sigmapharm Laboratories LLC, Sun Pharmaceutical Industries Ltd., VISEN Pharmaceuticals Co Ltd, and Wockhardt Ltd.. Also, the hypoparathyroidism market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: